This course has expired. View available courses.

Respirology

Expert Brief 3: Dual vs. Triple Therapy in Patients with a History of ≥ 1 Exacerbation in the Past Year

COPD is one of the most common conditions seen in primary care. With the many options that can be considered for these patients, it is important for primary care clinicians be aware of the current evidence to guide treatment. This series will review current evidence, compare it to current guidelines and apply it to common cases seen in clinical practice.


This program has received an unrestricted educational grant or in-kind support from GSK.

DURATION

15 min

PROFESSION

Physician

# OF CREDITS

0.3

ACCREDITATION

Mainpro+

EXPIRY DATE

2023-09-30

COPD is one of the most common conditions seen in primary care. With the many options that can be considered for these patients, it is important for primary care clinicians be aware of the current evidence to guide treatment. This series will review current evidence, compare it to current guidelines and apply it to common cases seen in clinical practice.


This program has received an unrestricted educational grant or in-kind support from GSK.

Faculty

John Axler, MD, LMCC, CCFP, FCFP
Andre Belanger, MD, CFPC
Jeff Habert, MD, CCFP, FCFP
Sol Stern, Bsc, MD, MCFP

Learning objectives

Upon completion of this continuing education program, participants will be better able to:

  • Contrast the current evidence supporting the use of dual bronchodilation (LAMA/LABA) versus triple therapy (ICS/LAMA/LABA) in a patient with a history of one acute exacerbation of (AECOPD) in the past year
  • Discuss the risk-benefit considerations in using LAMA/LABA versus ICS/LAMA/LABA

Accreditation

This self-learning program has been certified by the College of Family Physicians of Canada for up to 0.3 Mainpro+ credits.

This program is developed in collaboration with ICEBM.

Cost of course:  
Free
# of credits: 0.3
Duration: 15 min

FAQs & HELP

MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.

All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.

The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

No, registration with MDBriefCase is free!

To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.

If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.

Please note: if you submitted multiple password resets, only the link on the most recent email is valid.

You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.

Expert Brief 3: Dual vs. Triple Therapy in Patients with a History of ≥ 1 Exacerbation in the Past Year

15 min

Duration

Physician

Profession

0.3

# of credits

Learning Objectives

Upon completion of this continuing education program, participants will be better able to:

  • Contrast the current evidence supporting the use of dual bronchodilation (LAMA/LABA) versus triple therapy (ICS/LAMA/LABA) in a patient with a history of one acute exacerbation of (AECOPD) in the past year
  • Discuss the risk-benefit considerations in using LAMA/LABA versus ICS/LAMA/LABA

Mainpro+

ACCREDITATION

Respirology

Learning Category

COPD

Topic

0

Price

2023-09-30

Expiry Date

CAN-eng

Region/Language

Course Description

COPD is one of the most common conditions seen in primary care. With the many options that can be considered for these patients, it is important for primary care clinicians be aware of the current evidence to guide treatment. This series will review current evidence, compare it to current guidelines and apply it to common cases seen in clinical practice.


This program has received an unrestricted educational grant or in-kind support from GSK.

Faculty

John Axler, MD, LMCC, CCFP, FCFP
Andre Belanger, MD, CFPC
Jeff Habert, MD, CCFP, FCFP
Sol Stern, Bsc, MD, MCFP

Accreditation

This self-learning program has been certified by the College of Family Physicians of Canada for up to 0.3 Mainpro+ credits.

This program is developed in collaboration with ICEBM.